Insulin treatment in type 1 diabetes.

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Geremia B Bolli

Abstract

To present key aspects and strategies for use of insulin therapy in patients with type 1 diabetes mellitus. Limitations and advantages of various insulin regimens are discussed, and issues pertaining to insulin analogues are reviewed. Rapid-acting insulin analogues provide better and safer postprandial glucose coverage than does human regular insulin. Premixed insulin preparations do not provide the flexibility to address the individual needs of patients adequately to control postprandial glucose excursions. Because of its peak, short duration, and high variability, NPH insulin is inappropriate for patients with type 1 diabetes and patients with type 2 diabetes who require continuous basal coverage. Continuous infusion of soluble insulin by means of an insulin pump is currently the most physiologic approach available for treatment of type 1 diabetes. Use of insulin glargine or insulin detemir with a rapid-acting insulin analogue at meals is an effective and reasonable alternative to insulin pump therapy. Both rapid-acting and long-acting insulin analogues improve glycemic control. This improvement involves controlling hemoglobin A1c levels, reducing glucose excursions, and decreasing hypoglycemia, particularly during the night....Continue Reading

Citations

Feb 23, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Matthias ElsnerSigurd Lenzen
Mar 20, 2013·BMC Complementary and Alternative Medicine·Clautilde Mofor TeugwaDenis Zofou
Dec 7, 2007·Primary Care·Jeff Unger
Jun 19, 2007·Obstetrics and Gynecology Clinics of North America·Charanpal Singh, Lois Jovanovic
Feb 23, 2013·IEEE Transactions on Bio-medical Engineering·A RevertJ Bondia
Jun 3, 2015·Pediatric Transplantation·Molly O RegelmannRonen Arnon
Jan 1, 2007·Journal of Diabetes Science and Technology·David C Klonoff
Jan 15, 2010·International Journal of Radiation Biology·Yong Bin ChenG Z Guo
Feb 24, 2007·Diabetes Technology & Therapeutics·Reinhard H A Becker
Jun 24, 2021·Journal of Biomedical Informatics·Laura EvansMatvey B Palchuk

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Related Papers

The New England Journal of Medicine
Angelika MohnFrancesco Chiarelli
IEEE Transactions on Bio-medical Engineering
Malgorzata E WilinskaRoman Hovorka
© 2022 Meta ULC. All rights reserved